KR20130079146A - Compositoin for improving atopic dermatitis - Google Patents

Abstract

PURPOSE: A composition for treating atopic dermatitis is provided to apparently treat atopic dermatitis and to manufacture pharmaceutical products, food products, or cosmetic products. CONSTITUTION: A composition for treating atopic dermatitis contains fermentations which are prepared by lactic acid bacteria from one or more ingredients among Citrus unshiu peel, Ecklonia cava, and rice bran. The lactic acid bacteria are prepared by mixing Raphanus sativus powder, salts, sugar, and water, and naturally culturing. The composition further contains soybean powder and green tea powder.

Description

Composition for improving atopic dermatitis {Compositoin for Improving Atopic Dermatitis}

The present invention relates to an atopic dermatitis improving agent composition.

Atopy is a word derived from the Latin word "atopia", meaning "weird" or "inappropriate."

The cause of atopic dermatitis has not yet been elucidated, but increased IgE production, decreased number and decreased function of CD8 + suppressor / cytotoxic T lymphocytes, and Th1 (T-cell) secreting IFN-γ. Helper type 1) Decreased lymphocyte counts, monocyte / macrophage infiltration, mast cells, eosinophils, dendritic cells (DCs), epidermal Langerhans cells and CD4 + T lymphocytes, and Th2 cells compared to Th1 cells Immunological phenomena such as increased production of cytokines (IL-10, IL-4, IL-5, TNF-α, etc.) and increased production of chemokines (TSLP, RANTES, CTACK, LARC, MDC, TARC, etc.) Is being reported [J. Invest. Dermatol., 96: 523-526, 1991; J. Invest Dermatol., 97: 389-394, 1991; Immunol., 11: 81-88, 1999; Curr Drug Targets Inflamm Allergy., 2: 199-120, 2003; J. Allergy Clin Immunol., 107: 871-877, 2001; Adv. Immunol. 78:57, 2001; International Immunology, 14 (7): 767-773, 2002; Pediatr Allergy Immunol 19: 605-613, 2008], People with atopic dermatitis usually have allergic reactions to foreign objects such as house dust, mites, animal hair, food, pollen, and fungi, as well as atopy It is estimated that dermatitis is caused by disturbance of immune system in that it is accompanied by allergic rhinitis, asthma, conjunctivitis, enteritis.

Among the currently used therapeutic drugs, steroid drugs (adrenal corticosteroids) have excellent anti-inflammatory and immunosuppressive effects, but when used for a long time, they can cause hair to become thin and shrink, skin pigments and bacterial infections. It has side effects such as acne, skin thinning, and blood vessels.

Recently, in order to minimize side effects of existing chemicals, efforts to find natural products effective for atopic dermatitis have been actively made. Natural products that have been reported to improve atopic dermatitis include branched extracts, yonggyu, and mingled liquor mixed extracts (Domestic Patent No. 0589667), Aegean Swimming Extracts or Rhubarb Extracts (Domestic Patent No. 066829), Snake Strawberry Extract (Domestic Patent No. 066642). , Fungal fermented persimmon leaf extract (Domestic Patent Application No. 2010-0035674), guava leaf fermented product by the situation mushroom, etc. (Domestic Patent No. 0847104), and the like.

The present invention also discloses ameliorating activity of atopic dermatitis of fermented products by lactic acid bacteria of dermis, Ecklonia cava and / or rice bran as natural products.

An object of the present invention is to provide an atopic dermatitis improving composition.

Other and specific objects of the present invention will be presented below.

As the present inventors confirmed in the following Examples, Comparative Examples and Experimental Examples, when fermentation of dermis, Ecklonia cava, rice bran or a mixture thereof by the lactic acid bacteria, the beta-hexosaminidase free inhibitory activity of the fermentation dermis It was confirmed that the beta-hexosaminidase free inhibitory activity of the extract of Ecklonia cava or rice bran was significantly higher. In atopic dermatitis, mast cells show increased numbers and degranulation, and histamine released by degranulation is known to act on atopic dermatitis, alone or in combination with other factors (J Invest Dermatol. 102: 28-37 (1994)). ; Mini Rev Med Chem. 4 (9): 923-33 (2004); J Dermatol Sci. 33 (1): 23-9 (2003); J Drugs Dermatol. 3 (6): 632-9 (2004)) , RBL-2H3, a mast cell line, has a receptor of IgE antibody (FcεRI) on its surface, and when activated with IgE and antigen, degranulation is induced to secrete allergic mediators such as histamine. Hexosaminidase is known as an indicator of degranulation (Planta Med. 64: 577-578 (1998)).

In addition, the present inventors did not include these fermentation products when the clinical evaluation was performed using a cosmetic composition containing the dermis, Ecklonia cava and rice bran mixed fermentation product, which were shown to have excellent activity in the beta-hexosaminidase free inhibitory activity. Compared to the cosmetic composition of the comparative example it was confirmed that the SCORAD index is clearly dropped (SCORAD index was lowered from 39.52 ± 8.42 to 22.43 ± 13.62). The SCORAD index, developed by The European Task Force on Atopic Dermatitis, is the most widely used severity index of atopic dermatitis, and is usually classified as mild when the SCORAD index is 25 or less in the evaluation of atopic dermatitis severity through the SCORAD index. 55 people are classified as moderate, and 56 or more are classified as severe.

The present invention is provided based on the results of these experiments, and the present invention can be regarded as an atopic dermatitis improving agent composition in one aspect and an antihistamine composition in another aspect. The atopic dermatitis improving composition and the antihistamine composition of the present invention (hereinafter "composition of the present invention") is characterized in that it comprises a fermented product by the lactic acid bacteria of dermis, Ecklonia cava and / or rice bran as an active ingredient.

In the present specification, "dermis" refers to the peel of Jeju citrus sunki , which is a native of Jeju, and the physiological activity of the dermis has been reported antioxidant activity, antimicrobial activity, anti-inflammatory activity, blood pressure lowering activity (Jeong WS, Park SW, Chung SK.Food Sci.Biotechnol. 6: 292-296 (1997); Kim YC, Koh KS, Koh JS.Food Sci.Biotechnol. 10: 483-487 (2001); Cho C, Park BJ, Chung SH, Kim CB, Cha BS, Byun MW.Food Sci.Biotechnol. 13: 384-386 (2004); Murakami A, et al. Carcinogenesis 21: 1843-1850 (2000)).

In addition, in the present specification, the "rice bran" is a by-product obtained in the process of refining brown rice with white rice, and means that it includes rice snow and a whistle layer. It is to be understood that the rice bran is included in the rice bran as long as it includes the rice hull and the whistle layer, even though it additionally includes the outer skins and / or seedlings of the outer skin of brown rice and the endosperm and / or the endosperm.

In addition, in the present specification, the "atopic dermatitis" is meant to include all types of atopic dermatitis. Atopic dermatitis is generally classified into infantile atopic dermatitis, pediatric atopic dermatitis, adult atopic dermatitis, and maternal atopic dermatitis, depending on the time of its onset or the subject of the invention. Of atopic dermatitis.

In addition, in the present specification, the "improvement" is meant to include alleviation, prevention and / or treatment of symptoms.

In addition, in the present specification, the "active ingredient" refers to a component that shows activity alone or in combination with an adjuvant (carrier) having no activity.

Other terms not specifically defined in this specification are intended to refer to either a national language meaning or a commonly accepted meaning in the art.

The lactic acid bacteria that can be used for the preparation of the fermentation product as an active ingredient of the present invention can be used without any particular limitation, specifically, Lactobacillus genus Lactobacillus sp . ), Streptococcus spp. sp . , Pediococcus sp . , Leuconostoc sp . ) And a Bifidobacterium lactic acid bacteria (Bifidobacterium sp . ) Can be used. Preferably, however, the following examples used microorganisms naturally inoculated in a mixture of radish powder and salt, so that the lactic acid bacteria were inoculated into the salted vegetables and fermented so that the lactic acid bacteria were Leuconostoc ( Leuconostoc). kimchii ), Leuconostoc citreum), current Kono Stock mesen's steroid (Leuconostoc mesenteroides), current Kono Stock visible Komi tatum (Leuconostoc gasicomitatum ), Leuconostoc lactis ) and Lactobacillus plantarum, and / or Lactobacillus sakei . Most preferably, as in the following examples, the lactic acid bacteria preparations that are spawn cultured, that is, lactic acid bacteria preparations obtained by mixing salt, sugar and water in a beet powder and culturing them in a natural state. Here, "cultivate in natural state" means a state in which no artificial manipulation is applied in culture conditions such as temperature, humidity, CO ₂ concentration, inoculated microorganism, presence of oxygen, and the like.

Carbon and energy sources of lactic acid bacteria in the dermis, Ecklonia cava and / or rice bran in order to promote fermentation by the lactic acid bacteria before inoculating and fermenting the lactic acid bacteria in the dermis, Ecklonia cava and / or rice bran during the preparation of the fermented product, which is an active ingredient of the present invention. Can be added. As such a carbon source and an energy source, any known in the art can be used, and oligosaccharides, lactose, glucose, fructose, sugar, mixtures thereof, and the like will be used. These carbon sources and energy sources may be added in any range in consideration of the intended fermentation time, fermentation degree and the like. It will be added in the range of 3 to 30 parts by weight based on 100 parts by weight of dermis, Ecklonia cava and / or rice bran.

In addition, the fermentation by lactic acid bacteria for the production of fermented product of the active ingredient of the present invention can be made in the range of 15 ℃ ~ 45 ℃, preferably can be made in the range of 35 ℃ ~ 40 ℃. If the fermentation temperature is lower than the above range, the fermentation rate may be slow, and the desired fermentation product may be produced. If the fermentation temperature is higher than the above range, fermentation rate may be slowed or the desired fermentation product may be produced as the fermentation microorganisms are killed. have.

In addition, a fermentation step may be further included after the fermentation by lactic acid bacteria, which is to stabilize the fermentation products by the microorganisms after the growth of the inoculated microorganisms is stopped, such a fermentation step is performed for 3 days to 12 months Can be.

In addition, fermentation by lactic acid bacteria can be anaerobic or aerobic because it can be cultured under both anaerobic and aerobic conditions.

On the other hand, the following Examples and Experimental Example is a mixed fermentation of dermis, Ecklonia cava and rice bran its beta-hexosaminidase free inhibitory activity is significantly higher than the fermentation of each of dermis, Ecklonia cava and rice bran. Therefore, the active ingredient of the present invention is preferably obtained by fermenting a mixture of dermis, Ecklonia cava and rice bran by lactic acid bacteria. In addition, in the following examples, beta-hexosaminidase free inhibitory activity is also increased when green tea powder and soybean powder are added to the mixture and fermented. Therefore, the active ingredient of the present invention is more preferably obtained by fermenting a mixture of dermis, Ecklonia cava and rice bran added with green tea powder and soybean powder by lactic acid bacteria.

The fermented product, which is an active ingredient of the present invention, may be in the form of a liquid or powder obtained by concentrating the fermented product itself in a manner such as low temperature drying or freeze drying under reduced pressure. It may be in the form, or may be in the form of a liquid or powder obtained by concentrating and drying the filtrate and the filtered residue. It is also possible to extract the fermented product with an appropriate extraction solvent (for example, water, ethanol or a mixed solvent thereof).

On the other hand, the composition of the present invention may include the fermented product as an active ingredient in any amount (effective amount) as long as it can exhibit atopic dermatitis improving activity according to the properties, uses, formulations, formulation purposes, etc. of the fermentation product, An effective amount of phosphorus will be determined within the range of 0.001% to 15% by weight, based on the total weight of the composition. Specific effective amounts can be determined experimentally within the range of ordinary skill in the art.

The composition of the present invention can be used as a pharmaceutical composition in a specific embodiment.

The pharmaceutical composition of the present invention includes oral formulations (tablets, suspensions, granules, emulsions, capsules, syrups, etc.), parenteral formulations (sterilized), including pharmaceutically acceptable carriers, excipients, etc., in addition to the active ingredients thereof. Aqueous or oily suspensions for injection), topical formulations (solutions, creams, ointments, gels, lotions, patches) and the like.

As used herein, "pharmaceutically acceptable" means that the subject of application (prescription) does not have more toxicity (adequately low toxicity) to which the subject of application (prescription) is adaptable without inhibiting the activity of the active ingredient.

Examples of pharmaceutically acceptable carriers include lactose, glucose, sucrose, starch (such as corn starch, potato starch, etc.), cellulose, derivatives thereof (such as sodium carboxymethyl cellulose, ethylcellulose, etc.) malt, gelatin, talc, solids Lubricants (e.g. stearic acid, magnesium stearate, etc.), calcium sulfate, vegetable oils (e.g. peanut oil, cottonseed oil, sesame oil, olive oil, etc.), polyols (e.g. propylene glycol, glycerin, etc.), alginic acid, emulsifiers (e.g. TWEENS), wetting agents (e.g. Sodium lauryl sulfate), colorants, flavoring agents, tableting agents, stabilizers, antioxidants, preservatives, water, saline, phosphate buffer solutions and the like. The carrier may be selected from one or more of suitable pharmaceutical formulations according to the formulation of the pharmaceutical composition of the present invention.

Excipients may be selected and used according to the formulation of the pharmaceutical composition of the present invention, for example, when the pharmaceutical composition of the present invention is prepared with an aqueous suspending agent, suitable excipients are sodium carboxymethyl cellulose, methyl cellulose, hydropropylmethylcellulose And suspending agents and dispersing agents such as sodium alginate and polyvinylpyrrolidone. Suitable excipients when prepared from injection solutions include Ringer's solution, isotonic sodium chloride, and the like.

The pharmaceutical compositions of the present invention may be administered orally or parenterally, and may optionally be administered topically, as in the case of atopic dermatitis compositions.

The daily dose of the pharmaceutical composition of the present invention is usually 0.001 to 150 mg / kg body weight, and may be administered once or several times. However, since the dosage of the pharmaceutical composition of the present invention is determined in view of various related factors such as route of administration, age, sex, weight, and patient's severity of the patient, the dose is limited in any aspect to the scope of the present invention Should not be understood to be.

The composition of this invention can be grasped | ascertained by food compositions, such as a functional drink, in a specific aspect.

The food composition of the present invention may contain sweetening agents, flavoring agents, physiologically active ingredients, minerals and the like in addition to the active ingredients thereof.

Sweetening agents may be used in an amount that sweetens the food in a suitable manner, and may be natural or synthetic. Preferably, natural sweeteners are used. Examples of natural sweeteners include sugar sweeteners such as corn syrup solids, honey, sucrose, fructose, lactose and maltose.

Flavors may be used to enhance taste or flavor, both natural and synthetic. Preferably, a natural one is used. When using natural ones, the purpose of nutritional fortification can be performed in addition to the flavor. The natural flavor may be obtained from apples, lemons, citrus fruits, grapes, strawberries, peaches, and the like, or may be obtained from green tea leaves, round leaves, jujube leaves, cinnamon, chrysanthemum leaves, jasmine and the like. Also, those obtained from ginseng (red ginseng), bamboo shoots, aloe vera, banks and the like can be used. The natural flavoring agent may be a liquid concentrate or a solid form of extract. Synthetic flavors may be used depending on the case, and synthetic flavors such as esters, alcohols, aldehydes, terpenes and the like may be used.

As the physiologically active substance, catechins such as catechin, epicatechin, gallocatechin, epigallocatechin, vitamins such as retinol, ascorbic acid, tocopherol, calciferol, thiamine, riboflavin, and the like can be used.

As the mineral, calcium, magnesium, chromium, cobalt, copper, fluoride, germanium, iodine, iron, lithium, magnesium, manganese, molybdenum, phosphorus, potassium, selenium, silicon, sodium, sulfur, vanadium and zinc can be used.

In addition, the food composition of the present invention may contain preservatives, emulsifiers, acidifiers, thickeners and the like as needed in addition to the above sweeteners.

Such preservatives, emulsifiers and the like are preferably added in a very small amount as long as they can attain an application to which they are added. The term " trace amount " means, when expressed numerically, in the range of 0.0005% by weight to about 0.5% by weight based on the total weight of the food composition.

Examples of the preservative which can be used include calcium sodium sorbate, sodium sorbate, potassium sorbate, calcium benzoate, sodium benzoate, potassium benzoate and EDTA (ethylenediaminetetraacetic acid).

Examples of the emulsifier which can be used include acacia gum, carboxymethyl cellulose, xanthan gum, pectin and the like.

Examples of the acidulant that can be used include acid, malic acid, fumaric acid, adipic acid, phosphoric acid, gluconic acid, tartaric acid, ascorbic acid, acetic acid, and phosphoric acid. Such an acidulant may be added so that the food composition has a proper acidity for the purpose of inhibiting the growth of microorganisms other than the purpose of enhancing the taste.

Agents that may be used include suspending agents, sedimentation agents, gel formers, bulking agents and the like.

In addition, herbal medicines may be added to enhance flavor and palatability and to add other functionalities (such as preventing arthritis or osteoporosis). Extracts, tortoiseshell extracts, cornus extracts, goji berry extract, licorice extract, donkey extract, brown root extract, kangjinhyang extract, haphwanpi extract, mountain rump extract, lump extract, ginseng extract and the like can be exemplified.

In another aspect, the present invention can be understood as a cosmetic composition.

When the composition of the present invention is conceived as a cosmetic composition, the cosmetic composition can be prepared in various forms, for example, emulsions, lotions, creams (oil-in-water, water-in-oil, multiphase), solutions, suspensions (anhydrous and Aqueous), anhydrous products (oil and glycol based), gels, masks, packs or powders.

The composition of the present invention may contain an acceptable carrier in cosmetic preparations in addition to its active ingredients.

As used herein, the term " acceptable carrier for a cosmetic preparation "refers to a compound or composition which is already known and used in the cosmetic preparation, or which is a compound or composition to be developed in the future, and which is not toxic to the human body.

The carrier may be included in the composition of the present invention in an amount of from about 1% by weight to about 99.99% by weight, preferably from about 50% by weight to about 99% by weight of the composition, based on the total weight thereof.

However, since the ratio depends on the above-mentioned formulation of the cosmetic product and its specific application site (face or hands) or the desired amount of application thereof, the ratio is to limit the scope of the present invention in any aspect It should not be.

Examples of the carrier include alcohols, oils, surfactants, fatty acids, silicone oils, humectants, moisturizers, viscosifiers, emulsifiers, stabilizers, sunscreens, coloring agents and perfumes.

Alcohols, oils, surfactants, fatty acids, silicone oils, wetting agents, humectants, viscosity modifiers, emulsions, stabilizers, sunscreens, colorants, compounds / compositions that can be used as fragrances, etc., which can be used as the carrier are already known in the art. As a result, those skilled in the art can select and use appropriate materials / compositions.

As described above, according to the present invention, an atopic dermatitis improving agent composition may be provided. The atopic dermatitis improving agent composition of the present invention may be commercialized as a drug, food or cosmetics.

Hereinafter, the present invention will be described with reference to Examples, Comparative Examples, and Experimental Examples. However, the scope of the present invention is not limited to these examples, comparative examples and experimental examples.

< Example > dermis, Moth  Or rice bran Fermented  Produce

<Example 1> dermis fermentation preparation of

3.0 parts by weight of dermis powder was mixed with 100 parts by weight of water, and 1.0% by weight of sugar was added based on 100 parts by weight of sugar as a carbon source and energy source of microorganisms inoculated into the mixture, and 2% (v / v) was inoculated with a culture (about room temperature and aerobic conditions) in about 15 days to prepare a liquid dermal fermentation. Next, the liquid fermentation was sterilized at a sterilization temperature of 121 ° C. for about 20 minutes and concentrated under reduced pressure to obtain a solid fermentation product.

The lactobacillus spawn culture medium is added to 100 parts by weight of radish powder 100 parts by weight based on 100 parts by weight of salt and 400 parts by weight of water and 2.0 parts by weight of sugar which can be a carbon source and energy source of the microorganism by 35 to 50 ℃ Obtained by incubation for 15 days in the temperature range.

Example 2 Eckloniasis Preparation of Fermented Products

Ecklonia cava fermentation product was prepared in the same manner as in <Example 1>, but an Ecklonia cava fermentate was prepared using the same amount of Ecklonia cava powder instead of the dermis powder.

<Example 3> preparation of fermented rice bran

Rice bran fermented product was prepared in the same manner as in <Example 1>, but rice bran fermented product was prepared using the same amount of rice bran powder instead of dermis powder.

Example 4 Dermal, Ecklonia cava and Rice Bran Mixed Fermentation Production Example 1

The fermented product was prepared in the same manner as in <Example 1>, but instead of the dermis powder, the dermis, Ecklonia cava and rice bran mixture were used as 1.0 parts by weight based on 100 parts by weight of water, respectively. Prepared.

Example 5 Dermal, Ecklonia cava and Rice Bran Mixed Fermentation Production Example 2

In the same manner as in <Example 4> to prepare a fermentation product of dermis, Ecklonia cava and rice bran mixture, the fermentation product of dermis, Ecklonia cava and rice bran mixture by adding 0.5 parts by weight of soybean powder and green tea powder, based on 100 parts by weight of water, respectively. Prepared.

< Comparative example > dermis, Moth  Or preparation of rice bran extract

<Comparative Example 1> Preparation of dermis extract

30 parts by weight of dermal powder based on 100 parts by weight of ethanol and 100 parts by weight of 70% ethanol were stirred and extracted at room temperature for 24 hours. The extract was filtered with a 2 μm filter paper, and the filtrate was concentrated under reduced pressure to obtain a solid extract.

Comparative Example 2 Preparation of Ecklonia cava Extract

Ecklonia cava extract was prepared in the same manner as in <Comparative Example 1>, but an equivalent amount of ecstatic powder was used instead of the dermis powder.

Comparative Example 3 Preparation of Rice Bran Extract

Rice bran extract was prepared in the same manner as in <Comparative Example 1>, but the same amount of rice bran powder was used instead of the dermis powder.

< Experimental Example > Atopic dermatitis improvement activity experiment

<Experiment 1> Degranulation inhibitory activity measurement-β- hexosaminidase assay

The RBL-2H3 cell line was incubated in a 37 ° C., 5% CO ₂ incubator using Dulbeccos' modified Eagle's medium (DMEM) medium containing 10% FBS (Fetal bovine serum) and L-glutamine. After activating the RBL-2H3 cell line with monoclonal antibody IgE (0.5 μg / ml), the activated cells were treated with 200 ng / ml of antigen (DNP-HSA) and the samples of Examples and Comparative Examples were treated for 30 minutes. Incubated. The reaction was stopped by treatment in an ice bath for 10 minutes and then centrifuged. 0.02 ml of supernatant obtained by centrifugation was treated with 0.02 ml of substrate solution 1 mM p-NAG (p-nitrophenyl-N-acetyl-β-D-glucosaminide), which was then reacted at 37 ° C., 5% CO ₂ for 60 minutes. After the reaction, 0.2 ml of 0.1 M Na ₂ CO ₃ / NaHCO ₃ was added to stop the reaction. Absorbance was measured with an ELISA reader at 405 nm. The results are shown in Table 1 below with the concentrations required to inhibit 50% of the free inhibitory effect of beta-hexosaminidase (IC ₅₀ ). Inhibition of the amount of beta hexosaminidase secretion means preventing degranulation of immune cells and consequently having antihistamine activity.

Beta-hexosaminidase free inhibitory activity (IC ₅₀ , μg / ml) sample IC ₅₀ (占 퐂 / ml) Example 1 96.5 Example 2 146.7 Example 3 79.4 Example 4 63.2 Example 5 61.5 Comparative Example 1 187.6 Comparative Example 2 286.9 Comparative Example 3 128.4

The results in Table 1 show that all of the fermented products of dermis, Ecklonia cava and rice bran have higher beta-hexosaminidase free inhibitory activity than extracts of dermis, Ecklonia cava and rice bran. In particular, the fermentation product of <Example 4> which is a mixed fermentation product of dermis, Ecklonia cava and rice bran, and the fermentation product of <Example 5> which is a mixed fermentation product to which soybean and green tea are added have high activity.

Experimental Example 2 Clinical Evaluation of Atopic Dermatitis Improvement Activity

Clinical evaluation of the atopic dermatitis improving activity was performed by preparing a cosmetic composition containing a mixed fermentation of dermis, Ecklonia cava and rice bran of <Example 4> showed excellent activity in the <Experimental Example 1>.

The cosmetic composition of the Preparation Example is 3.0% by weight of the mixed fermentation of dermis, Ecklonia cava and rice bran, 3.0% by weight of cetyl alcohol, 3.0% by weight of glycerin, 3.0% by weight of 1,3-butylglycol, polysorbate 20 0.2 wt%, sodium hyaluronate 2.0 wt%, paraffin 4.0 wt%, squalane 4.0 wt%, fragrance 0.05 wt% and the residual amount of purified water were used, and the cosmetic composition of the comparative example is the < The cosmetic composition prepared by further containing purified water as the content of the mixed fermentation of dermis, Ecklonia cava and rice bran of Example 4> was used.

Clinical evaluation Ten patients over 5 years of age with atopic dermatitis were divided into two heels and applied to the affected area twice daily for a total of four weeks.

The improvement in atopic dermatitis after 4 weeks was assessed by the SCORAD index developed by The European Task Force on Atopic Dermatitis (higher levels of atopic symptoms).

The results were expressed as Mean ± SD, ANOVA analysis was performed, and the significant difference was verified by Duncan test ( p <0.05 and ** is p <0.01).

The results are shown in [Table 2] below.

SCORAD Index division Before application (average value) After application (average value) Manufacturing example 39.52 ± 8.42 22.43 ± 13.62 ** Comparative example 32.53 ± 12.64 33.72 ± 10.29

The results of Table 2 indicate that the cosmetic composition of the preparation example containing the mixed fermentation of dermis, Ecklonia cava and rice bran of <Example 4> showed a clear atopic dermatitis improving activity, but the cosmetic of Comparative Example which did not contain the fermentation product The composition shows no atopic dermatitis improving activity.

Claims (9)

Atopic dermatitis improving composition comprising a fermented product by at least one lactic acid bacteria selected from the group consisting of dermis, Ecklonia cava and rice bran as an active ingredient.
The method of claim 1,
The active ingredient is an atopic dermatitis improving composition, characterized in that the fermented product by the lactic acid bacteria of the mixture of dermis, Ecklonia cava and rice bran.
The method of claim 1,
The lactic acid bacteria is atopic dermatitis improving composition, characterized in that obtained by mixing the salt and sugar and water in the radish powder and culturing it in a natural state.
The method of claim 2,
Soybean powder and green tea powder are added to the mixture, characterized in that the atopic dermatitis improving composition.
Atopic dermatitis improving composition comprising a fermented product by at least one lactic acid bacteria selected from the group consisting of dermis, Ecklonia cava and rice bran as an active ingredient.
The method of claim 5,
The active ingredient is an atopic dermatitis improving composition, characterized in that the fermented product by the lactic acid bacteria of the mixture of dermis, Ecklonia cava and rice bran.
The method of claim 5,
The lactic acid bacteria is atopic dermatitis improving composition, characterized in that obtained by mixing the salt and sugar and water in the radish powder and culturing it in a natural state.
The method according to claim 6,
Soybean powder and green tea powder are added to the mixture, characterized in that the atopic dermatitis improving composition.
The method according to any one of claims 1 to 8,
The composition is an atopic dermatitis improving composition, characterized in that the pharmaceutical composition, cosmetic composition or food composition.